Brenda J. Weigel

8.6k total citations · 2 hit papers
164 papers, 5.8k citations indexed

About

Brenda J. Weigel is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Brenda J. Weigel has authored 164 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Molecular Biology, 62 papers in Oncology and 56 papers in Neurology. Recurrent topics in Brenda J. Weigel's work include Neuroblastoma Research and Treatments (54 papers), Sarcoma Diagnosis and Treatment (43 papers) and Cancer therapeutics and mechanisms (19 papers). Brenda J. Weigel is often cited by papers focused on Neuroblastoma Research and Treatments (54 papers), Sarcoma Diagnosis and Treatment (43 papers) and Cancer therapeutics and mechanisms (19 papers). Brenda J. Weigel collaborates with scholars based in United States, Switzerland and Canada. Brenda J. Weigel's co-authors include Susan M. Blaney, Elizabeth Fox, Stephan D. Voss, Joel M. Reid, Bruce R. Blazar, Peter C. Adamson, Charlotte H. Ahern, Charles G. Minard, Ashish M. Ingle and Yaël P. Mossé and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Brenda J. Weigel

160 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

2011 532 citations Qing Zhou, Meghan E. Munger et al. Blood profile →
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

2013 477 citations Yaël P. Mossé, Stephan D. Voss et al. profile →

Peers

Countries citing papers authored by Brenda J. Weigel

Since Specialization

Citations

This map shows the geographic impact of Brenda J. Weigel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brenda J. Weigel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brenda J. Weigel more than expected).

Fields of papers citing papers by Brenda J. Weigel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brenda J. Weigel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brenda J. Weigel. The network helps show where Brenda J. Weigel may publish in the future.

Co-authorship network of co-authors of Brenda J. Weigel

This figure shows the co-authorship network connecting the top 25 collaborators of Brenda J. Weigel. A scholar is included among the top collaborators of Brenda J. Weigel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brenda J. Weigel. Brenda J. Weigel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pilot study to evaluate automated laboratory data transfer into Medidata Rave for NCI-supported pediatric cooperative group trials in the Pediatric Early Phase Clinical Trials Network (PEP-CTN) and Pediatric Brain Tumor Consortium (PBTC). 2024 ·Journal of Clinical Oncology ·Tamara P. Miller, Richard Aplenc, Charles G. Minard, Yu Wang, Shelly Lensing, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Brenda J. Weigel, (unknown), Elizabeth Fox	0
2	A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 2022 ·Clinical Cancer Research ·Kara L. Davis, Elizabeth Fox, (unknown), Joel M. Reid, (unknown), Charles G. Minard, Stephan D. Voss, Stacey L. Berg, Brenda J. Weigel, Crystal L. Mackall	43
3	Successful management of an arteriovenous malformation with trametinib in a patient with capillary‐malformation arteriovenous malformation syndrome and cardiac compromise 2022 ·Pediatric Dermatology ·Cynthia L. Nicholson, Siobhan Flanagan, (unknown), Christina Boull, (unknown), Rebecca Ameduri, Brenda J. Weigel, Sheilagh Maguiness	35
4	Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) 2021 ·Clinical Cancer Research ·Jennifer H. Foster, Stephan D. Voss, David Hall, Charles G. Minard, Frank M. Balis, Keith D. Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, Yaël P. Mossé	61
5	A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515) 2021 ·Pediatric Blood & Cancer ·Thomas F. Cash, Elizabeth Fox, Xiaowei Liu, Charles G. Minard, Joel M. Reid, Adrienne C. Scheck, Brenda J. Weigel, Cynthia Wetmore	23
6	Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors 2021 ·Cancer Medicine ·Leo Mascarenhas, Chitose Ogawa, Theodore W. Laetsch, Brenda J. Weigel, Michael W. Bishop, (unknown), Scott C. Borinstein, Emily K. Slotkin, Jodi A. Muscal, Pooja Hingorani, Donna E. Levy, Gary Mo, Ashwin Shahir, Jennifer Wright, Steven G. DuBois	2
7	Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report 2021 ·Neuro-Oncology ·Jack Su, Lindsay Kilburn, David B. Mansur, Mark Krailo, Allen Buxton, (unknown), Amar Gajjar, Peter C. Adamson, Brenda J. Weigel, Elizabeth Fox, Susan M. Blaney, Maryam Fouladi	39
8	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study 2020 ·Cancer ·James I. Geller, Joseph G. Pressey, Malcolm A. Smith, Rachel A. Kudgus, Mariana M. Cajaiba, Joel M. Reid, David Hall, Donald A. Barkauskas, (unknown), Steve Y. Cho, Stacey L. Berg, Jeffrey S. Dome, Elizabeth Fox, Brenda J. Weigel	30
9	Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312) 2019 ·Clinical Cancer Research ·Kristina A. Cole, Sharmistha Pal, Rachel A. Kudgus, Heba Ijaz, Xiaowei Liu, Charles G. Minard, Bruce Pawel, John M. Maris, Daphne A. Haas‐Kogan, Stephan D. Voss, Stacey L. Berg, Joel M. Reid, Elizabeth Fox, Brenda J. Weigel	48
10	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) 2019 ·Clinical Cancer Research ·Yaël P. Mossé, Elizabeth Fox, David T. Teachey, Joel M. Reid, Stephanie L. Safgren, Hernán Carol, Richard B. Lock, Peter J. Houghton, Malcolm A. Smith, David Hall, Donald A. Barkauskas, Mark Krailo, Stephan D. Voss, Stacey L. Berg, Susan M. Blaney, Brenda J. Weigel	79
11	Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411) 2019 ·Pediatric Blood & Cancer ·Eric S. Schafer, Rachel E. Rau, Stacey L. Berg, Xiaowei Liu, Charles G. Minard, Alexander J.R. Bishop, July Carolina Romero, John Hicks, Marvin D. Nelson, Stephan D. Voss, Joel M. Reid, Elizabeth Fox, Brenda J. Weigel, Susan M. Blaney	52
12	A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314) 2018 ·Pediatric Blood & Cancer ·Eric S. Schafer, Rachel E. Rau, Stacey L. Berg, Xiaowei Liu, Charles G. Minard, David R. D’Adamo, Rachael Scott, Larisa Reyderman, (unknown), (unknown), Joel M. Reid, Elizabeth Fox, Brenda J. Weigel, Susan M. Blaney	14
13	Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group 2017 ·Pediatric Blood & Cancer ·Erin R. Rudzinski, James R. Anderson, Yueh‐Yun Chi, Julie M. Gastier‐Foster, Caroline Astbury, Frederic G. Barr, Stephen X. Skapek, Douglas S. Hawkins, Brenda J. Weigel, Alberto S. Pappo, William H. Meyer, Michael Arnold, Lisa A. Teot, David M. Parham	65
14	A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report 2014 ·Clinical Cancer Research ·Maryam Fouladi, John P. Perentesis, Lars M. Wagner, Alexander A. Vinks, Joel M. Reid, Charlotte H. Ahern, George Thomas, Carol A. Mercer, Darcy A. Krueger, Peter J. Houghton, L. Austin Doyle, Helen Chen, Brenda J. Weigel, Susan M. Blaney	16
15	Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report 2013 ·Journal of Clinical Oncology ·Julia Glade Bender, Alice Lee, Joel M. Reid, Sylvain Baruchel, Timothy P. L. Roberts, Stephan D. Voss, Bing Wu, Charlotte H. Ahern, Ashish M. Ingle, Pamela Jo Harris, Brenda J. Weigel, Susan M. Blaney	125
16	A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report 2012 ·Clinical Cancer Research ·Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda J. Weigel, Diana Stempak, Frank M. Balis, Susan M. Blaney	90
17	A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report 2012 ·Clinical Cancer Research ·Julia Glade Bender, Susan M. Blaney, Scott C. Borinstein, Joel M. Reid, Sylvain Baruchel, Charlotte H. Ahern, Ashish M. Ingle, Darrell J. Yamashiro, Alice P. Chen, Brenda J. Weigel, Peter C. Adamson, Julie R. Park	16
18	Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group 2011 ·Journal of Clinical Oncology ·Suman Malempati, Brenda J. Weigel, Ashish M. Ingle, Charlotte H. Ahern, Julie M. Carroll, Charles T. Roberts, Joel M. Reid, Stephen C. Schmechel, Stephan D. Voss, (unknown), Helen X. Chen, Mark Krailo, Peter C. Adamson, Susan M. Blaney	147
19	Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia 2010 ·Blood ·Qing Zhou, Meghan E. Munger, Steven L. Highfill, Jakub Tolar, Brenda J. Weigel, Megan Riddle, Arlene H. Sharpe, Daniel A. Vallera, Miyuki Azuma, Bruce L. Levine, Carl H. June, William J. Murphy, David H. Munn, Bruce R. Blazar	230
20	Killing the Killer: Natural Killer Cells to Treat Ewing's Sarcoma 2010 ·Clinical Cancer Research ·Yong‐Oon Ahn, Brenda J. Weigel, Michael R. Verneris	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact